• Share Purchase Plan closed with valid applications for A$2.65 million
• New shares issued at $0.18 each, exceeding original target of A$2.5 million
• Proceeds to support ACCENT and AMPLICITY trials, and potential pivotal phase 2b/3 trial for lead drug narmafotinib in 2H 2026

Amplia Therapeutics Limited (ASX: ATX) has announced that its Share Purchase Plan (SPP) closed on Friday, 22 August 2025 with valid applications received for A$2.65 million worth of new shares, exceeding the original target of A$2.5 million. The new shares will be issued at $0.18 each, which is the lower of the Placement Offer Price of $0.23 and a 5% discount to the 5-day volume weighted average price. The SPP was part of a broader A$27.65 million capital raising that also included an institutional placement. The proceeds from the capital raising will be used to support the ACCENT and AMPLICITY trials, as well as potential investigator-initiated trials, of the company's lead drug narmafotinib (AMP945). The funds will also enable Amplia to accelerate towards commencement of a potential pivotal phase 2b/3 trial for AMP945 in the second half of 2026. Following the successful capital raising, the company will be funded into 2027.

The proceeds from the A$27.65 million capital raising, including the A$2.65 million raised through the Share Purchase Plan, will support the ACCENT and AMPLICITY trials, and enable Amplia to accelerate towards commencement of a potential pivotal phase 2b/3 trial for its lead drug narmafotinib (AMP945) in the second half of 2026.

The successful capital raising will provide Amplia with the funds to support its ongoing clinical studies and plan for future trials of narmafotinib, the company's lead drug candidate, as it looks to advance the program towards a potential pivotal phase 2b/3 trial in the second half of 2026.